Ofloxacin is a new fluoride quinolone which has been shown to be active both in vitro and in vivo against Mycobacterium tuberculosis. This prospective study presents the results obtained with a new protocol for the treatment of genito-urinary tuberculosis. The comparison drugs were Ofloxacin 200 mg every 12 hours for 6 months, Rifampicin 600 mg every 24 for 3 months and Isoniazid 300 mg every 24 hours for 3 months. The results, were clinically and microbiologically good. It is concluded that this new drug should be a valid alternative to the traditional therapy.